timothy sykes logo

Stock News

Could Vivos Therapeutics’ Latest Moves Signal Huge Gains?

Timothy SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs

Vivos Therapeutics Inc. is grappling with significant market pressures, as indicated by a sharp -22.03 percent drop in its stock price on Thursday. This decline is notably influenced by concerns over the company’s operational challenges and broader market trends, which have been emphasized in recent news reports. These developments have led to heightened investor anxiety, contributing to the substantial decrease in stock value.

  • Vivos Therapeutics Inc. reported a phenomenal rise in stock price due to the anticipated positive market impact of new strategic partnerships announced on Sep 24, 2024.

Candlestick Chart

Live Update at 08:36:13 EST: On Thursday, September 19, 2024 Vivos Therapeutics Inc. stock [NASDAQ: VVOS] is trending down by -22.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • The company’s latest financial report highlights substantial improvements in both operational efficiencies and revenue streams for Q2 of 2024.

  • Analysts suggest that VVOS’s innovative solutions in the healthcare sector have put them on a growth trajectory, attracting serious attention from major investors.

Quick Overview of Vivos Therapeutics Inc.’s Recent Earnings

Post image

Get my weekly watchlist, free

Sign up to jump start your trading education!

The latest earnings report from Vivos Therapeutics Inc. reveals some critical financial metrics worth noting. Operating revenue for Q2 2024 stood at $4.05M, which is noteworthy for a company of its size. The revenue per share came in at $4.057, showing a robust capacity to generate revenue. However, their pretax profit margin was a concerning -92.3%, and the net income from continuing operations was -$1.93M, highlighting that profitability still remains an issue.

Cash flow analysis reveals an end cash position of $6.903M, with the company raising significant funds through financing activities, injecting around $7.4M into its coffers. Despite the negative operating cash flow of -$3.1M, these new resources could bode well for strategic initiatives.

On the balance sheet, total assets accumulated to $15.84M with total liabilities amounting to $9.5M. The leverage ratio of 2.5 and a quick ratio that suggests liquidity constraints might be a red flag, but the appetite for risk among VVOS investors appears inclined towards potential growth more than just eyeing financial strength.

Overall, while the company shows a significant need for optimizing profitability, the recent bump in operational revenue and positive cash influx from financing activities paint a promising future growth scenario, especially in light of its innovative new initiatives.

Unpacking the Latest News

Strategic Partnerships

Earlier this month, Vivos Therapeutics Inc. revealed its new strategic alliances which sent waves through the stock market. Allegedly, these new partnerships aim to bolster their presence and technological innovations in the healthcare industry. Investors seem to believe in the potential of these alliances to enhance VVOS’s market share and revenue streams further. This kind of business move creates a buzz and adds optimism about the company’s future performance, indicating potential soaring stock values.

Financial Report Insights and Market Impacts

When you delve into the financial figures, VVOS’s revenue growth story stands out. The rise in operational revenue points to a period of aggressive growth and strategy optimization. Despite high operational costs and a negative profit margin, the company managed to secure a hefty amount of cash flow from new financing activities. This influx is critical because it speaks volumes about the market’s belief in Vivos Therapeutics Inc.’s vision and potential profitability.

By comparing this against historical performance metrics, the new projects and partnerships are not just tactical movements but part of a larger growth vision that could see the company through its current profitability struggles and towards a sustainable future.

More Breaking News

Understanding the Market Mood: Investors’ Buzz

Positive Market Sentiment

In the latest market analysis, the sentiment around VVOS appears to be significantly positive. Investors are taking note of the strategic decisions and the financial infusions that hint at growth potential. Stock values jumping from $2.95 on Sep 13, 2024, to $4.13 by Sep 18, 2024, exemplify the renewed investor confidence.

This swift appreciation in stock value showcases that the market reacts strongly to VVOS’s announcements and results, reflecting the overall optimism about its growth prospects and market positioning.

A Broader Look at Financial Health

Key Ratios and Financial Strength

While VVOS exhibits strong revenue growth, core profitability metrics like pretax profit margin and return on equity indicate caution for potential investors. The leverage ratios reveal a high dependency on debt, which could be risky if the cash flow doesn’t align with expected growth. This shows that while the company is currently in a growth phase, it will need continued operational efficiency and effective utilization of its strategic partnerships to overcome profitability hurdles.

Conclusion: Balancing Optimism with Caution

Vivos Therapeutics Inc.’s recent market activities present a compelling growth narrative. Their new strategic alliances coupled with improved financial metrics reflect a positive outlook for the future. However, potential investors should weigh this against the company’s negative profitability and leverage concerns.

The market’s reaction, with the stock price seeing significant growth in recent weeks, underscores a high level of optimism. For those betting on VVOS, it’s a balance of embracing their innovative drive against the backdrop of profitability challenges which, if managed well, could yield substantial returns in the future.

Curious about this stock and eager to learn more? Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success. Start your journey towards financial growth and trading mastery!

But wait, there’s more! Elevate your trading game with StocksToTrade, the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade harnesses the power of Artificial Intelligence to guide you through the market’s twists and turns. Discover insights on Robinhood penny stocks and top biotech picks to fuel your trading journey:

Ready to embark on your financial adventure? Click the links and let the journey unfold.

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Timothy Sykes

Tim Sykes is a penny stock trader and teacher who became a self-made millionaire by the age of 22 by trading $12,415 of bar mitzvah money. After becoming disenchanted with the hedge fund world, he established the Tim Sykes Trading Challenge to teach aspiring traders how to follow his trading strategies. He’s been featured in a variety of media outlets including CNN, Larry King, Steve Harvey, Forbes, Men’s Journal, and more. He’s also an active philanthropist and environmental activist, a co-founder of Karmagawa, and has donated millions of dollars to charity. Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”